• Something wrong with this record ?

Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight

H. Višnová, E. Papaleo, FS. Martin, K. Koziol, BM. Klein, B. Mannaerts

. 2021 ; 43 (6) : 1019-1026. [pub] 20210903

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22011864

RESEARCH QUESTION: How does the efficacy and safety of individualized follitropin delta dosing compare with conventional dosing for ovarian stimulation in potential high responders? DESIGN: Retrospective analysis of 153 potential high responders identified on the basis of baseline serum anti-Müllerian hormone (AMH) levels above 35 pmol/l, who were originally randomized to an individualized fixed dose of follitropin delta based on AMH and body weight (n = 78) or to a daily starting dose of 150 IU follitropin alfa (n = 75). RESULTS: At the end of stimulation, patients treated with individualized follitropin delta or conventional follitropin alfa had 12.1 ± 7.0 and 18.3 ± 7.0 (P < 0.001) follicles measuring 12 mm or wider, and 27.3% and 62.7% had serum progesterone levels higher than 3.18 nmol/l (P < 0.001), respectively. Overall number of oocytes in these two respective arms was 9.3 ± 6.7 and 17.9 ± 8.7 (P < 0.001), and the ongoing pregnancy rate per started cycle after fresh blastocyst transfer was 28.2% and 24.0%. The risk of ovarian hyperstimulation syndrome (OHSS) for all cases was three times higher in the conventional follitropin alfa arm at 16.0% versus 5.1% with individualized follitropin delta treatment (P = 0.025) and 26.7% versus 7.7% (P = 0.001) for early moderate or severe OHSS, preventive interventions for early OHSS, or both. CONCLUSIONS: Treatment with individualized follitropin delta provides an improved efficacy-safety balance in women with high ovarian reserve, as it normalizes the ovarian response and decreases the risk of OHSS without compromising the chance of pregnancy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011864
003      
CZ-PrNML
005      
20220506130356.0
007      
ta
008      
220425s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rbmo.2021.08.024 $2 doi
035    __
$a (PubMed)34756645
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Višnová, Hana $u IVF Cube, Fertility Clinic, Evropská 423, Prague 160 00, Czech Republic
245    10
$a Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight / $c H. Višnová, E. Papaleo, FS. Martin, K. Koziol, BM. Klein, B. Mannaerts
520    9_
$a RESEARCH QUESTION: How does the efficacy and safety of individualized follitropin delta dosing compare with conventional dosing for ovarian stimulation in potential high responders? DESIGN: Retrospective analysis of 153 potential high responders identified on the basis of baseline serum anti-Müllerian hormone (AMH) levels above 35 pmol/l, who were originally randomized to an individualized fixed dose of follitropin delta based on AMH and body weight (n = 78) or to a daily starting dose of 150 IU follitropin alfa (n = 75). RESULTS: At the end of stimulation, patients treated with individualized follitropin delta or conventional follitropin alfa had 12.1 ± 7.0 and 18.3 ± 7.0 (P < 0.001) follicles measuring 12 mm or wider, and 27.3% and 62.7% had serum progesterone levels higher than 3.18 nmol/l (P < 0.001), respectively. Overall number of oocytes in these two respective arms was 9.3 ± 6.7 and 17.9 ± 8.7 (P < 0.001), and the ongoing pregnancy rate per started cycle after fresh blastocyst transfer was 28.2% and 24.0%. The risk of ovarian hyperstimulation syndrome (OHSS) for all cases was three times higher in the conventional follitropin alfa arm at 16.0% versus 5.1% with individualized follitropin delta treatment (P = 0.025) and 26.7% versus 7.7% (P = 0.001) for early moderate or severe OHSS, preventive interventions for early OHSS, or both. CONCLUSIONS: Treatment with individualized follitropin delta provides an improved efficacy-safety balance in women with high ovarian reserve, as it normalizes the ovarian response and decreases the risk of OHSS without compromising the chance of pregnancy.
650    _2
$a dospělí $7 D000328
650    _2
$a antimülleriánský hormon $x krev $7 D054304
650    _2
$a porodnost $7 D001723
650    _2
$a tělesná hmotnost $x fyziologie $7 D001835
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fertilizace in vitro $x metody $7 D005307
650    _2
$a folikuly stimulující hormon lidský $x aplikace a dávkování $7 D043373
650    _2
$a lidé $7 D006801
650    _2
$a ovariální hyperstimulační syndrom $x krev $x etiologie $7 D016471
650    _2
$a indukce ovulace $x škodlivé účinky $7 D010062
650    _2
$a těhotenství $7 D011247
650    _2
$a úhrn těhotenství na počet žen v reprodukčním věku $7 D018873
650    _2
$a progesteron $x krev $7 D011374
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $7 D011994
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Papaleo, Enrico $u IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132
700    1_
$a Martin, Fernando Sánchez $u Ginemed, Calle Farmaceutico Murillo Herrera 3 Sevilla 41010, Spain
700    1_
$a Koziol, Katarzyna $u nOvum Fertility Clinic, Bociania 13 Warsaw 02-807, Poland
700    1_
$a Klein, Bjarke M $u Ferring Pharmaceuticals, Global Biometrics, Kay Fiskers Plads 11, Copenhagen DK-2300, Denmark
700    1_
$a Mannaerts, Bernadette $u Ferring Pharmaceuticals, Reproductive Medicine and Maternal Health, Kay Fiskers Plads 11, Copenhagen DK-2300, Denmark. Electronic address: Bernadette.Mannaerts@ferring.com
773    0_
$w MED00007348 $t Reproductive biomedicine online $x 1472-6491 $g Roč. 43, č. 6 (2021), s. 1019-1026
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34756645 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130349 $b ABA008
999    __
$a ok $b bmc $g 1789455 $s 1163065
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 43 $c 6 $d 1019-1026 $e 20210903 $i 1472-6491 $m Reproductive biomedicine online $n Reprod Biomed Online $x MED00007348
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options